🔎 Trials Near Me

Home › Kanser sa Bato (Renal Cell Carcinoma) › Georgia

Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Georgia

12 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Georgia.

Mga Lungsod sa Georgia

Opisyal na teksto ng pag-aaral (English)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05536141

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Winship Cancer Institute of Emory University, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Northeast Georgia Medical Center Braselton, Braselton
  • Atlanta VA Medical Center, Decatur
  • Northeast Georgia Medical Center-Gainesville, Gainesville
  • at 4 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • Emory Saint Joseph's Hospital, Atlanta
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04981509

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102), Marietta
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07489495

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Tennessee Oncology, PLLC- Ringgold, Ringgold
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • Emory University - Winship Cancer Institute, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT06582017

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05433142

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Winship Cancer Institute - Emory University, Atlanta
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT04198766

A Beta-only IL-2 ImmunoTherapY Study

  • Emory - Winship Cancer Institute, Atlanta
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2025 · NCT05086692

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.